Brief: SMS Pharmaceuticals says PMDA (Japan) inspection at Bachupally facility concludes with no critical observations
Aug 23 (Reuters) - Sms Pharmaceuticals Ltd SMSP.NS :
* PMDA (Japan) inspection at manufacturing facility -
unit-II, located at Bachupally, Hyderabad concluded with no
critical observations
Source text: (http://bit.ly/2wmyq8n)
Further company coverage: SMSP.NS
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on SMS Pharmaceuticals
See all newsBrief: SMS Pharmaceuticals Ltd Q2 Consol Net Profit INR 398.5 Million
Brief: SMS Pharmaceuticals March-Quarter Consol Net Profit 327.1 Million Rupees
Brief: Sms Pharmaceuticals Says Tax Demand Reduced To 4 Million Rupees From 71.9 Million Rupees
Advisory: Alert incorrectly tagged to SMS Phramaceuticals withdrawn
Brief: SMS Pharmaceuticals Says Completion Of USFDA Inspection At Vizag Manufacturing Facility